BeBetter Med Inc (688759)

Currency in CNY
35.57
+0.59(+1.69%)
Closed·
688759 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
32.6836.08
52 wk Range
27.5357.47
Key Statistics
Bid/Ask
35.55 / 35.59
Prev. Close
34.98
Open
34.64
Day's Range
32.68-36.08
52 wk Range
27.53-57.47
Volume
6.52M
Average Volume (3m)
4.62M
1-Year Change
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688759 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Earnings

Latest Release
Apr 27, 2026
EPS / Forecast
-0.12 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

688759 Income Statement

Compare 688759 to Peers and Sector

Metrics to compare
688759
Peers
Sector
Relationship
P/E Ratio
−92.3x31.9x−0.4x
PEG Ratio
-0.270.00
Price/Book
9.7x2.2x2.6x
Price / LTM Sales
-6.0x3.0x
Upside (Analyst Target)
-31.1%54.6%
Fair Value Upside
Unlock6.7%9.7%Unlock

BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for oncology, metabolic diseases and central nervous system degenerative diseases. It offers BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; developing BEBT-209, a CDK4/6 selective inhibitor for metastatic triple-negative breast cancer; and BEBT-109, a selective EGFR inhibitor designed for NSCLC. The company also develops BEBT-503, an oral, well-balanced pan-PPAR for metabolic diseases including diabetes and mash; BEBT-507, a GalNAc-siRNA drug for Polycythemia Vera (PV); and BEBT-701, a GalNAc-siRNA therapeutic for treatment of hypertension with co-existing hyperlipidemia. In addition, it provides BEBT-809, a small molecule inhibitor for obesity; BEBT-706, for ASCVD risk reduction; BEBT-720, for mash; BEBT-758, for the treatment of Parkinson's disease; BEBT-756, for Alzheimer's disease; BEBT-730, for hyperuricemia and gout; BEBT-733, for renal anemia/CKD; and BEBT-738, for diabetes. The company was founded in 2012 and is based in Guangzhou, China.

Employees
160
Market
China

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.17M1.59%250.97M
Other Institutional Investors
192.05M42.68%6.72B
Public Companies & Retail Investors
250.81M55.73%8.77B
Total
450.04M100.00%15.74B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Guangzhou Yaoqing Investment Partnership (Limited Partnership)6.87%30,926,9581,081,825
Yingke Innovation Asset Management Co., Ltd.4.79%21,555,153753,999

FAQ

What Is the BeBetter Med (688759) Stock Price Today?

The BeBetter Med stock price today is 35.57 CNY.

What Stock Exchange Does BeBetter Med Trade On?

BeBetter Med is listed and trades on the Shanghai Stock Exchange.

What Is the Stock Symbol for BeBetter Med?

The stock symbol for BeBetter Med is "688759."

What Is the BeBetter Med Market Cap?

As of today, BeBetter Med market cap is 15.74B CNY.

What Is BeBetter Med's Earnings Per Share (TTM)?

The BeBetter Med EPS (TTM) is -0.42.

From a Technical Analysis Perspective, Is 688759 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has BeBetter Med Stock Split?

BeBetter Med has split 0 times.

How Many Employees Does BeBetter Med Have?

BeBetter Med has 160 employees.

What is the current trading status of BeBetter Med (688759)?

As of Jul 21, 2026, BeBetter Med (688759) is trading at a price of 35.57 CNY, with a previous close of 34.98 CNY. The stock has fluctuated within a day range of 32.68 CNY to 36.08 CNY, while its 52-week range spans from 27.53 CNY to 57.47 CNY.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.